All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FIT-013a
Therapeutic Area: Oncology Product Name: EMB-01
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: China Merchants Bank International
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 23, 2021
Details:
Proceeds from the financing will be used to fund the ongoing clinical development of EMB-01, EMB-02 and EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-115
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
Results from this study showed that APG-115 has therapeutic potential in NSCLC harboring STK11 mutations, and shows the potential of a new treatment option for the subgroup of patients with drug resistance to approved PD-1 inhibitors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GLR2007
Therapeutic Area: Oncology Product Name: GLR2007
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2021
Details:
GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor that Gan & Lee is developing for the treatment of advanced solid tumors including glioblastoma, an aggressive form of brain cancer with a low survival rate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-2575
Therapeutic Area: Oncology Product Name: APG-2575
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2021
Details:
APG-2575 is a novel, orally administered small-molecule Bcl-2‒selective inhibitor. APG-2575 is designed to treat hematologic malignancies and solid tumors by selectively blocking antiapoptotic protein Bcl-2 to restore the normal apoptosis process in cancer cells.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
